Select Publications

Belani CP et al. Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel
or observation. J Clin Oncol 2003;21(15):2933-9. Abstract

Cho BC et al. Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib. J Clin Oncol 2007;25(18):2528-33. Abstract

Douillard J-Y et al. Gefitinib (IRESSA) versus docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer pre-treated with platinum-based chemotherapy:
A randomized, open-label Phase III study (INTEREST). Proc 12th World Conference on Lung Cancer 2007;Abstract PRS-02.

Fehrenbacher L et al. A phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of bevacizumab in combination with either chemotherapy (docetaxel
or pemetrexed) or erlotinib hydrochloride compared with chemotherapy alone for treatment of recurrent or refractory non-small cell lung cancer. Proc ASCO 2006;Abstract 7062.

Gatzemeier U et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007;25(12):1545-52. Abstract

Gradishar WJ et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol
2005;23(31):7794-803. Abstract

Greco A et al. Albumin bound paclitaxel wkly + carboplatin: First-line therapy for advanced NSCLC. Proc Chemotherapy Foundation Symposium XXIV 2006. No abstract available

Grønberg BH et al. A phase III study by the Norwegian Lung Cancer Group: Pemetrexed + carboplatin vs gemcitabine + carboplatin as first-line chemotherapy in stage IIIB/IV non-small cell lung cancer. IASLC Meeting 2007;Abstract A3-04.

Hanna N et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22(9):1589-97. Abstract

Hawkins MJ et al. Study of three weekly nab-paclitaxel regimens in combination with carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC). Proc ASCO 2007;Abstract 7659.

Heymach JV et al. A phase II trial of ZD6474 plus docetaxel in patients with previously treated NSCLC: Follow-up results. Proc ASCO 2006;Abstract 7016.

Le Calvez F et al. TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: Distinct patterns in never, former, and current smokers. Cancer Res 2005;65(12):5076-83. Abstract

Manegold C et al. Randomized, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naïve patients with
advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704. Proc ASCO 2007;Abstract LBA7514.

Reynolds C et al. An open-label, phase II trial of nanoparticle albumin bound paclitaxel (nab-paclitaxel), carboplatin, and bevacizumab in first-line patients with advanced non-squamous non-small cell lung cancer (NSCLC). Proc ASCO 2007;Abstract 7610.

Sandler A et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355(24):2542-50. Abstract

Scagliotti GV et al. A randomized phase III trial of cisplatin and pemetrexed versus cisplatin and gemcitabine in patients with locally advanced or metastatic non-small cell lung cancer. Proc 12th World Conference on Lung Cancer 2007;Abstract PRS-03.

Toyooka S et al. The impact of sex and smoking status on the mutational spectrum of epidermal growth factor receptor gene in non small cell lung cancer. Clin Cancer Res 2007;13(19):5763-8. Abstract

Wakelee H et al. Optimal adjuvant therapy for non-small cell lung cancer — How to handle stage I disease. Oncologist 2007;12:331-7. Abstract

Home

EDITOR
Neil Love, MD

INTERVIEWS
Paul A Bunn Jr, MD
- Select publications

Nasser H Hanna, MD
- Select publications

Antoinette J Wozniak, MD
- Select publications

A CME Audio Series and Activity

Faculty Disclosures

Editor's Office